Cantor Fitzgerald reissued their overweight rating on shares of Eli Lilly and Company (NYSE:LLY – Free Report) in a report released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $630.00 price objective on the stock.
Several other research firms also recently weighed in on LLY. Jefferies Financial Group upgraded Eli Lilly and Company from a hold rating to a buy rating and increased their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. Citigroup boosted their target price on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the company a buy rating in a report on Wednesday, July 26th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the stock an overweight rating in a research report on Wednesday, August 9th. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the company an overweight rating in a research note on Monday, October 9th. Finally, StockNews.com lowered Eli Lilly and Company from a buy rating to a hold rating in a research report on Wednesday, October 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $555.83.
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.25 earnings per share. Research analysts expect that Eli Lilly and Company will post 6.65 EPS for the current year.
Insider Buying and Selling at Eli Lilly and Company
In other news, major shareholder Lilly Endowment Inc sold 3,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $528.13, for a total transaction of $1,584,390.00. Following the sale, the insider now directly owns 100,696,849 shares of the company’s stock, valued at $53,181,026,862.37. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 3,000 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $528.13, for a total value of $1,584,390.00. Following the completion of the sale, the insider now directly owns 100,696,849 shares of the company’s stock, valued at $53,181,026,862.37. The disclosure for this sale can be found here. Insiders sold a total of 907,655 shares of company stock valued at $21,078,714,805 in the last ninety days. Insiders own 0.13% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Silicon Valley Capital Partners acquired a new position in Eli Lilly and Company in the first quarter worth $25,000. Retirement Group LLC lifted its position in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the last quarter. Bogart Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 193.3% in the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after buying an additional 58 shares during the period. Laffer Tengler Investments bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $33,000. Finally, Cornerstone Planning Group LLC acquired a new stake in Eli Lilly and Company during the second quarter worth about $33,000. Institutional investors own 81.38% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More
- Five stocks we like better than Eli Lilly and Company
- How to Invest in Blue Chip Stocks
- Las Vegas Sands Stock May No Longer Be a Gamble
- The How and Why of Investing in Biotech Stocks
- MarketBeat ‘Stock of the Week’: Is Gen Digital Undervalued?
- Best Aerospace Stocks Investing
- The Value Deepens for Medtech Stocks: Reversal Imminent
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
